Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with the final act in a pharmaceutical saga, the debate of Vertex Pharmaceuticals’ success, and news on 23andMe’s ongoing transformation.
The need-to-know this morning
- Novo Nordisk said it is increasing the availability of its blockbuster obesity drug Wegovy for new U.S. patients. The Danish drugmaker reported a 31% increase in sales for 2023 and issued better-than-expected guidance for 2024.
- GSK reported fourth quarter and 2023 earnings, and so did Novartis.
Adieu to Aduhelm
Years after a polarizing FDA decision and an ensuing commercial disaster, Biogen is finally parting ways with Aduhelm, its first approved medicine for Alzheimer’s disease.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect